AUSTIN, TX, UNITED STATES, August 11, 2026 /EINPresswire.com/ — INNOVOTEX Inc., a pharmaceutical company developing Macrocycle Drug Conjugates (MDCs) designed to improve the therapeutic index of established cancer therapies, today announced the close of a strategic financing that will fund IND-enabling development of its lead oncology candidate, NOVO-111. The financing was led by Bull Life Sciences, reflecting a shared long-term commitment to the company’s development strategy and providing INNOVOTEX with a well-capitalized lead investor as it advances toward key milestones.
This financing arrives as venture capital in biotechnology has rebounded in 2026 but remains highly selective, concentrating on companies with differentiated science and clear development pathways.
“This financing represents a defining milestone for INNOVOTEX and validates both our scientific approach and disciplined development strategy,” said Dr. Krystle Karoscik, CEO of INNOVOTEX. “It enables us to advance NOVO-111 through IND-enabling studies while positioning the company for strategic partnerships with pharmaceutical organizations seeking innovative oncology assets.”
NOVO-111 is a Macrocycle Drug Conjugate engineered to enhance tumor-selective delivery of oxaliplatin while reducing systemic exposure, with the goal of improving efficacy and minimizing the dose-limiting toxicities that often restrict conventional platinum chemotherapy. INNOVOTEX will be following a more efficient regulatory path by expediting development via a 505(b)(2) pathway towards an IND submission, a strategy that was confirmed by the U.S. Food and Drug Administration.
Proceeds will support the critical activities required for an IND application, including manufacturing scale-up, GLP toxicology, pharmacology, and regulatory-enabling studies. These efforts are expected to position NOVO-111 for clinical evaluation and create multiple value-inflection points in the coming months.
With Bull Life Sciences as lead investor, INNOVOTEX is well positioned to execute its development strategy with the support of a long-term capital partner. The financing also strengthens the company’s ability to expand partnering discussions with global pharmaceutical companies seeking differentiated oncology technologies. Industry demand remains strong for innovative preclinical and early-stage assets that can help replenish oncology pipelines.
“Bull Life Sciences is committed to backing exceptional management teams pursuing transformative innovation,” said Danny Stapleton, Executive Chairman and CEO. “We are excited to continue supporting INNOVOTEX as it advances its development program and expands opportunities for pharmaceutical partnerships.”
As large pharmaceutical companies continue to seek external innovation, INNOVOTEX believes its Macrocycle Drug Conjugate platform offers a differentiated approach to enhancing clinically validated therapies while addressing longstanding limitations of conventional chemotherapy.
About INNOVOTEX:
INNOVOTEX is a biotechnology company developing Macrocycle Drug Conjugates (MDCs) that enhance the precision, delivery, and therapeutic index of established oncology medicines. Its lead program, NOVO-111, is designed to improve tumor-selective delivery of platinum chemotherapy with the goal of maximizing anti-tumor activity while reducing systemic toxicity. Through advanced molecular engineering, INNOVOTEX is creating next-generation therapeutics that build on proven biological mechanisms to improve outcomes for patients with cancer.
Krystle Karoscik
INNOVOTEX Inc.
email us here
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
